Markets
BCRX

BioCryst Pharma Appoints Babar Ghias As CFO

July 07, 2025 — 07:44 am EDT

Written by RTTNews.com for RTTNews->

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX), a biotechnology company, on Monday announced the appointment of Babar Ghias as Chief Financial Officer and Head of corporate development.

Ghias has been working as CFO since 2022 at AvenCell Therapeutics.

Chief Executive Officer Jon Stonehouse said the addition of these skills and expertise to the leadership team is exactly what we need at this time.

In the pre-market trading, BioCryst Pharmaceuticals is 0.45% lesser at $8.90 on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

BCRX

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.